Alembic Pharmaceuticals secures USFDA approval for new Paliperidone extended-release tablets
Alembic Pharmaceuticals Limited has achieved a major milestone in the pharmaceutical industry. On September 27, 2024, the company proudly announced that it received final approval from the United States Food and Drug Administration (USFDA) for its Paliperidone Extended-Release Tablets in strengths of 1.5 mg, 3 mg, 6 mg, and 9 mg. This approval marks a […]
